Skip to main content

Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

  • Poster presentation
  • Open access
  • Published:

Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)


Recurrent or metastatic SCCHN has few effective therapeutic options. In these patients, the EXTREME regimen added Cetuximab--an EGFR-specific monoclonal antibody--to a regimen of Platinum/5-FU and improved median overall survival (OS) by 2.7 months and progression-free survival (PFS) by 2.3 months [1]. Given the natural killer (NK) cell-mediated antibody dependent cellular cytotoxicity (ADCC) of Cetuximab-mediated tumor killing and the immunogenic antitumor effects of chemotherapeutics like Platinum and 5-FU, synergy with immunotherapy may be one option to further improve outcomes.

VTX-2337 (Motolimod), a novel Toll-like receptor 8 (TLR8) agonist, stimulates myeloid dendritic cells (mDC), monocytes, and NK cells. Preclinical data have demonstrated increased ADCC with IgG1 monoclonal antibodies when Motolimod is added [2] as well as synergistic effects when Motolimod is combined with chemotherapy [3]. A Phase Ib study of Cetuximab and Motolimod in patients with Platinum-refractory or -intolerant recurrent or metastatic SCCHN has shown the combination to be both tolerable and active in this setting [4]. Translational medicine correlates demonstrated TLR8 activation and enhanced NK cell mobilization and activation. There is strong rationale to further assess the safety, tolerability, and efficacy of this combination in SCCHN patients. A large trial in this population will allow exploration of a number of translational medicine correlates to illuminate the combination of immunotherapy with other anti-cancer therapies.


This randomized, double-blind, placebo-controlled, Phase II study evaluates the safety and efficacy of Motolimod with EXTREME vs. EXTREME alone for first-line treatment of recurrent or metastatic SCCHN. Patients must have a confirmed diagnosis, measurable disease, and no prior systemic therapy for their recurrent or metastatic disease. Approximately 175 patients will be randomized 1:1 to receive Motolimod or placebo + EXTREME for 6 cycles (q3wk), followed by weekly Cetuximab with biweekly Motolimod/placebo. The primary objective is to compare PFS according to immune-related response evaluation criteria between the two treatment arms, as determined by independent review. Secondary objectives include comparisons of safety and OS between the two treatment groups.

Translational studies will be conducted to compare immune biomarker response by a multiplexed panel of cytokines, chemokines, and inflammatory markers; genetic polymorphisms that may impact response to a TLR8 agonist or to Cetuximab; and the effect of immune cell subsets within the tumor on response to treatment and/or clinical outcome between the two treatment groups. Pharmacokinetics of Motolimod will also be evaluated. Enrollment began in October 2013. (NCT01836029)


  1. Vermorken JB, Mesia R, Rivera F, et al: Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008, 1116-27.

    Google Scholar 

  2. Stephenson RM, Lim CL, Matthews M, et al: TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother. 2013, 62 (8): 1347-57. 10.1007/s00262-013-1437-3. Aug

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Monk B, Brady M, Lankes H, et al: VTX-2337, a TLR8 Agonist, Plus Chemotherapy in Recurrent Ovarian Cancer: Preclinical and Phase 1 Data by the Gynecology Oncology Group. American Society of Clinical Oncology Annual Meeting. 2013, June 3-7, Chicago, IL, USA

    Google Scholar 

  4. Chow L, Eaton K, Baik C, et al: Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN). Int J Radiat Oncol Biol Phys. 2014, 88: 503-504.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferris, R.L., Cohen, E., Gash, K. et al. Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). j. immunotherapy cancer 2 (Suppl 3), P69 (2014).

Download citation

  • Published:

  • DOI: